导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -14.26% | 4072/4773 |
| 近一周 | -2.29% | 3689/5465 |
| 近一月 | 0.17% | 658/5421 |
| 近一季 | -8.21% | 3165/5231 |
| 近半年 | -17.08% | 4223/4920 |
| 近一年 | 0.08% | 2756/4394 |
| 近两年 | 48.85% | 1538/2954 |
| 近三年 | 17.68% | 1571/2253 |
| 成立以来 | 75.11% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.70% 3675/4961 |
-0.71% 3311/5312 |
- - |
- - |
| 2025 | 33.45% 1117/4813 |
-1.59% 2704/3635 |
12.15% 110/4076 |
7.83% 3430/4524 |
12.14% 143/4813 |
| 2024 | 9.44% 1468/3463 |
-6.09% 2006/2808 |
-2.11% 1138/3014 |
13.26% 2206/3129 |
5.12% 637/3463 |
| 2023 | -9.61% 1200/2656 |
1.36% 1587/2280 |
3.42% 96/2385 |
-10.27% 1978/2515 |
-3.90% 818/2655 |
| 2022 | -25.26% 1302/2207 |
-22.38% 1696/1919 |
4.01% 1068/2016 |
-7.13% 114/2113 |
-0.31% 1591/2208 |
| 2021 | 18.31% 210/1822 |
-18.09% 1205/1255 |
11.67% 364/1330 |
9.27% 139/1466 |
18.37% 35/1822 |
| 2020 | 77.20% 50/1250 |
-1.14% 205/1028 |
10.88% 753/1067 |
33.36% 5/1164 |
21.21% 56/1184 |
| 2019 | 20.57% 664/1092 |
31.38% 203/754 |
-9.78% 690/804 |
3.36% 257/850 |
-1.58% 902/918 |
| 2018 | -27.96% 430/834 |
- - |
- - |
- - |
-12.79% 484/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 易方达中证军工ETF VS. 长安沪深300非周期A(740101) |